Question explored with the scientific record
Is aerobika device useful for bronchiectasis
Short version: the Aerobika hasn't been tested in bronchiectasis. The device class has, but weakly.
The evidence for OPEP in bronchiectasis itself is thin. A 2014 systematic review collected six small trials of oscillating PEP devices (Flutter, Acapella), each with 8 to 36 patients, quality scores of 3 to 7 out of 10 [4]. It found effects on sputum and quality of life, not on exacerbations, hospitalizations, or death. A 2025 narrative review of non-drug bronchiectasis therapies notes the whole airway clearance field is dominated by short-term, single-session studies with heterogeneous outcomes and limited long-term data on infection, inflammation, or flare-ups [3]. None of the retrieved records tested the Aerobika specifically in bronchiectasis.
| Technique comparison | Finding |
|---|---|
| ELTGOL vs placebo, 12 months | 13 vs 16 exacerbations, fewer in active group [6] |
| ELTGOL vs placebo, sputum 24h | +17 mL favor ELTGOL at 12 months [6] |
| AD/ELTGOL vs TPEP, in-session | TPEP lower by ~3 g sputum, 24h similar [5] |
| oPEP vs control, COPD flare-ups 3 mo | 8 OPEP vs 10 control [2] |
The best-designed trial here is ELTGOL (a breathing technique, not the Aerobika) against a genuine placebo over a year, and it showed fewer exacerbations and more sputum cleared [6]. That establishes the principle that clearing sputum helps. It does not prove the Aerobika does the same. The closest direct comparison found temporary PEP (TPEP) cleared less sputum in-session than two other techniques, though 24-hour totals were similar [5].
Device hygiene is an underrated risk. In a cystic fibrosis study, 28 of 30 airway clearance devices were contaminated before cleaning, including 4 Aerobika units [1]. Cleaning helped but did not eliminate everything.
My call: reasonable to try if you produce sputum and can stand the routine, but the direct evidence for the Aerobika is essentially absent, so treat it as an unproven option and clean it rigorously. Confidence: low.
Sources used 6
-
Cleaning and infection control of airway clearance devices used by CF patients
This study evaluated whether airway clearance devices used by cystic fibrosis patients are contaminated after use, whether standard nebulizer cleaning guidelines reduce contamination, and what the findings imply for infection control and CF microbiology.
DOI: 10.1177/1479972317707652 -
Comparison of effectiveness of temporary positive expiratory pressure versus oscillatory positive expiratory pressure in severe COPD patients
This study compares the effectiveness of Temporary Positive Expiratory Pressure (T-PEP) and Oscillatory Positive Expiratory Pressure (O-PEP) in reducing exacerbations and improving respiratory function in patients with severe COPD, finding that T-PEP significantly reduces exacer…
DOI: 10.1111/crj.12661 -
Addressing treatable traits in bronchiectasis through non-pharmacological therapies: a narrative review
This narrative review synthesizes evidence on nonpharmacological therapies addressing treatable traits in adults with bronchiectasis, highlighting airway clearance techniques, rehabilitation, and lifestyle/nutrition interventions and their clinical effects.
DOI: 10.21037/jtd-2024-2106 -
The effects of oscillating positive expiratory pressure therapy in adults with stable non-cystic fibrosis bronchiectasis
This systematic review evaluates the efficacy of oscillating positive expiratory pressure (PEP) therapy in enhancing sputum expectoration and quality of life in adults with stable non-cystic fibrosis bronchiectasis compared to other airway clearance techniques.
DOI: 10.1177/1479972314562407 -
Short-term effects of three slow expiratory airway clearance techniques in patients with bronchiectasis: a randomised crossover trial
In adults with bronchiectasis, a randomized crossover trial compared three slow expiratory airway clearance techniques (autogenic drainage, ELTGOL, and TPEP); AD and ELTGOL increased sputum expectoration during sessions vs TPEP, but 24-hour clearance and quality-of-life improvem…
DOI: 10.1016/j.physio.2015.07.005 -
Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial
This randomized, placebo-controlled trial evaluates whether twice-daily ELTGOL airway clearance improves mucus clearance, reduces exacerbations, and enhances quality of life over 12 months in adults with bronchiectasis and chronic productive cough, compared with placebo.
DOI: 10.1183/13993003.01926-2017